Angiotensin-Converting Enzyme Inhibitors in Patients With Coronary Artery Disease and Absence of Heart Failure or Left Ventricular Systolic Dysfunction: An Overview of Long-term Randomized Controlled Trials | Cardiology | JAMA Internal Medicine | JAMA Network
[Skip to Navigation]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address 18.204.227.34. Please contact the publisher to request reinstatement.
1.
Flather  MDYusuf  SKober  L  et al.  Long-term ACE-inhibitor therapy in patients with heart failure or left-ventricular dysfunction: a systematic overview of data of individual patients.  Lancet 2000;3551575- 1581PubMedGoogle ScholarCrossref
2.
Rodrigues  EJEisenberg  MJPilote  L Effects of early and late administration of angiotensin-converting enzyme inhibitors on mortality after myocardial infarction.  Am J Med 2003;115473- 479PubMedGoogle ScholarCrossref
3.
Yusuf  SSleight  PPogue  JBosch  JDavies  RDagenais  GThe Heart Outcomes Prevention Evaluation Study investigators, Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients..  N Engl J Med 2000;342145- 153[published correction appear in N Engl J Med. 2000;342:748 and 2000;242:1376]PubMedGoogle ScholarCrossref
4.
Fox  KM European Trial on Reduction of Cardiac Events With Perindopril in Stable Coronary Artery Disease investigators. Efficacy of perindopril on reduction of cardiovascular events among patients with stable coronary artery disease: randomised, double-blind, placebo-controlled multicentre trial (the EUROPA study).  Lancet 2003;362782- 788PubMedGoogle ScholarCrossref
5.
Braunwald  EDomanski  MJFowler  SE  et al. PEACE trial investigators, Angiotensin-converting-enzyme inhibition in stable coronary artery disease.  N Engl J Med 2004;3512058- 2068PubMedGoogle ScholarCrossref
6.
 Antithrombotic Trialists' Collaboration. Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients.  BMJ 2002;32471- 86[published correction appears in BMJ. 2002;324:141]PubMedGoogle ScholarCrossref
7.
Freemantle  NCleland  JYoung  PMason  JHarrison  J β-Blockade after myocardial infarction: systematic review and meta regression analysis.  BMJ 1999;3181730- 1737PubMedGoogle ScholarCrossref
8.
Heart Protection Study Collaborative Group, MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial.  Lancet 2002;3607- 22PubMedGoogle ScholarCrossref
9.
Snow  VBarry  PFihn  SD  et al.  Primary care management of chronic stable angina and asymptomatic suspected or known coronary artery disease: a clinical practice guideline from the American College of Physicians.  Ann Intern Med 2004;141562- 567PubMedGoogle ScholarCrossref
10.
Pitt  BO'Neill  BFeldman  R  et al.  The QUinapril Ischemic Event Trial (QUIET): evaluation of chronic ACE inhibitor therapy in patients with ischemic heart disease and preserved left ventricular.  Am J Cardiol 2001;871058- 1063PubMedGoogle ScholarCrossref
11.
Nissen  SETuzcu  EMLibby  P  et al. CAMELOT Investigators, Effect of antihypertensive agents on cardiovascular events in patients with coronary disease and normal blood pressure: the CAMELOT study; a randomized controlled trial.  JAMA 2004;2922217- 2226PubMedGoogle ScholarCrossref
12.
Teo  KKBurton  JRButler  CE  et al.  Long-term effects of cholesterol lowering and angiotensin-converting enzyme inhibition on coronary atherosclerosis: the Simvastatin/Enalapril Coronary Atherosclerosis Trial (SCAT).  Circulation 2000;1021748- 1754PubMedGoogle ScholarCrossref
13.
MacMahon  SSharpe  NGamble  G  et al. PART-2 Collaborative Research Group, Randomized, placebo-controlled trial of the angiotensin-converting enzyme inhibitor, ramipril, in patients with coronary or other occlusive arterial disease.  J Am Coll Cardiol 2000;36438- 443PubMedGoogle ScholarCrossref
14.
Kjoller-Hansen  LSteffensen  RGrande  P The Angiotensin-converting Enzyme Inhibition Post Revascularization Study (APRES).  J Am Coll Cardiol 2000;35881- 888PubMedGoogle ScholarCrossref
15.
Moher  DCook  DJEastwood  SOlkin  IRennie  DStroup  DF Improving the quality of reports of meta-analyses of randomised controlled trials: the QUOROM statement: quality of reporting of meta-analyses.  Lancet 1999;3541896- 1900PubMedGoogle ScholarCrossref
16.
Altman  DGSchulz  KF Statistics notes: concealing treatment allocation in randomised trials.  BMJ 2001;323446- 447PubMedGoogle ScholarCrossref
17.
Juni  PAltman  DGEgger  M Systematic reviews in health care: assessing the quality of controlled clinical trials.  BMJ 2001;32342- 46PubMedGoogle ScholarCrossref
18.
Juni  PWitschi  ABloch  REgger  M The hazards of scoring the quality of clinical trials for meta-analysis.  JAMA 1999;2821054- 1060PubMedGoogle ScholarCrossref
19.
Greenland  S Invited commentary: a critical look at some popular meta-analytic methods.  Am J Epidemiol 1994;140290- 296PubMedGoogle Scholar
20.
Cucherat  MBoissel  JPLeizorovicz  AHaugh  MC EasyMA: a program for the meta-analysis of clinical trials.  Comput Meth Programs Biomed 1997;53187- 190Google ScholarCrossref
21.
Begg  CBMazumdar  M Operating characteristics of a rank correlation test for publication bias.  Biometrics 1994;501088- 1101PubMedGoogle ScholarCrossref
22.
Lees  RSPitt  BChan  RC  et al.  Baseline clinical and angiographic data in the Quinapril Ischemic Event (QUIET) Trial.  Am J Cardiol 1996;781011- 1016PubMedGoogle ScholarCrossref
23.
Texter  MLees  RSPitt  BDinsmore  REUprichard  AC The Quinapril Ischemic Event Trial (QUIET) design and methods: evaluation of chronic ACE inhibitor therapy after coronary artery intervention.  Cardiovasc Drugs Ther 1993;7273- 282PubMedGoogle ScholarCrossref
24.
The HOPE Study investigators, The HOPE (Heart Outcomes Prevention Evaluation) Study: the design of a large, simple randomized trial of an angiotensin-converting enzyme inhibitor (ramipril) and vitamin E in patients at high risk of cardiovascular events.  Can J Cardiol 1996;12127- 137PubMedGoogle Scholar
25.
Teo  KKBurton  JRBuller  CPlante  SYokoyama  SMontague  TJSCAT Investigators, Rationale and design features of a clinical trial examining the effects of cholesterol lowering and angiotensin-converting enzyme inhibition on coronary atherosclerosis: Simvastatin/Enalapril Coronary Atherosclerosis Trial (SCAT).  Can J Cardiol 1997;13591- 599PubMedGoogle Scholar
26.
Gomma  AHFox  KM The EUROPA trial: design, baseline demography and status of the substudies.  Cardiovasc Drugs Ther 2001;15169- 179PubMedGoogle ScholarCrossref
27.
Pfeffer  MADomanski  MRosenberg  Y  et al.  Prevention of events with angiotensin-converting enzyme inhibition (the PEACE study design).  Am J Cardiol 1998;8225H- 30HPubMedGoogle ScholarCrossref
28.
Yusuf  SPogue  J ACE inhibition in stable coronary artery disease.  N Engl J Med 2005;352937- 938PubMedGoogle ScholarCrossref
29.
Oosterga  MVoors  AAPinto  YM  et al.  Effects of quinapril on clinical outcome after coronary artery bypass grafting (the QUO VADIS study).  Am J Cardiol 2001;87542- 546PubMedGoogle ScholarCrossref
30.
Multicenter European Research Trial with Cilazapril After Angioplasty to Prevent Transluminal Coronary Obstruction and Restenosis (MERCATOR) Study Group, Does the new angiotensin converting enzyme inhibitor cilazapril prevent restenosis after percutaneous transluminal coronary angioplasty? results of the MERCATOR study: a multicenter, randomized, double-blind placebo-controlled trial.  Circulation 1992;86100- 110PubMedGoogle ScholarCrossref
31.
Faxon  DPMulticenter American Research Trial With Cilazapril After Angioplasty to Prevent Transluminal Coronary Obstruction and Restenosis (MARCATOR) Study Group, Effect of high-dose angiotensin-converting enzyme inhibition on restenosis: final results of the MARCATOR study, a multicenter, double-blind, placebo-controlled trial of cilazapril.  J Am Coll Cardiol 1995;2362- 369Google ScholarCrossref
32.
Desmet  WVrolix  MDe Scheerder  IVan Lierde  JWillems  JLPiessens  J Angiotensin-converting enzyme inhibition with fosinopril sodium in the prevention of restenosis after coronary angioplasty.  Circulation 1994;89385- 392PubMedGoogle ScholarCrossref
33.
Meurice  TBauters  CHermant  X  et al.  Effects of ACE inhibitors on angiographic restenosis after coronary stenting (PARIS): a randomised, double blind, placebo-controlled trial.  Lancet 2001;3571321- 1324PubMedGoogle ScholarCrossref
34.
Kaul  UChandra  SBahl  VKSharma  SWasir  HS Enalapril for prevention of restenosis after coronary angioplasty.  Indian Heart J 1993;45469- 473PubMedGoogle Scholar
35.
Yamabe  TImazu  MYamaoto  H  et al.  Effect of cilazapril in vascular restenosis after percutaneous transluminal coronary angioplasty.  Coronary Artery Dis 1995;6573- 579Google Scholar
36.
Otsuka  MYamamoto  HOkimoto  T  et al.  Long-term effects of quinapril with high affinity for tissue angiotensin-converting enzyme after coronary intervention in Japanese.  Am Heart J 2004;147662- 668PubMedGoogle ScholarCrossref
37.
Sadamatsu  KShimokawa  HTashiro  HYamamoto  K Long-term treatment with enalapril reduces plasma concentrations of macrophage colony stimulating factor in patients with coronary artery disease.  Heart 2001;86457- 458PubMedGoogle ScholarCrossref
38.
Di Mario  CStrikwerda  SGil  RAzar  ARames  ASerruys  PW Long-term changes in the response of conductance and resistance coronary vessels to endothelium-dependent and independent vasodilators: a double-blind placebo-controlled study of the effect of a 6-month treatment with cilazapril.  Ital Heart J 2000;1674- 683PubMedGoogle Scholar
39.
Mancini  GBHenry  GCMacaya  C  et al.  the TREND (Trial on Reversing Endothelial Dysfunction) Study. Angiotensin-converting enzyme inhibition with quinapril improves endothelial vasomotor dysfunction in patients with coronary artery disease.  Circulation 1996;94258- 265PubMedGoogle ScholarCrossref
40.
Esper  RJMachado  RVilarino  J  et al.  Endothelium-dependent resonses in patients with hypercholesterolemic coronary artery disease under the effects of simvastatin and enalapril, either separately or combined.  Am Heart J 2000;140684- 689PubMedGoogle ScholarCrossref
41.
Anderson  TJElstein  EHaber  HCharbonneau  F Comparative study of ACE-inhibition, angiotensin II antagonism, and calcium-channel blockade on flow-mediated vasodilatin in patients with coronary disease (BANFF study).  J Am Coll Cardiol 2000;3560- 66PubMedGoogle ScholarCrossref
42.
Toyofyuku  MImazu  MSumii  K  et al.  Influence of angiotensinogen M253T gene polymorphism and an angiotensin-converting enzyme inhibitor on restenosis after percutaneous coronary intervention.  Atherosclerosis 2002;160339- 344PubMedGoogle ScholarCrossref
43.
Koh  KKSon  JWAhn  JY  et al.  Vascular effects of simvastatin combined with ramipril in hypercholesterolemic patients with coronary artery disease, compared with simvastatin alone: a randomized, double-blind, placebo-controlled, crossover study.  Atherosclerosis 2004;177147- 153PubMedGoogle ScholarCrossref
44.
Thurmann  PRietbrock  N Angiotensin-converting enzyme inhibition with spirapril in patients with coronary artery disease.  Blood Press 1994;2 ((suppl)) 73- 76Google Scholar
45.
Kaski  JCRosano  GGavrielides  SChen  L Effects of angiotensin-converting enzyme inhibition on exercise-induced angina and ST segment depression in patients with microvascular angina.  J Am Coll Cardiol 1994;23652- 657PubMedGoogle ScholarCrossref
46.
van den Heuvel  AFDunselman  PHKingma  T  et al.  Reduction of exercise-induced myocardial ischemia during add-on treatment with the angiotensin-converting enzyme inhibitor enalapril in patients with normal left ventricular function and optimal beta-blockage.  J Am Coll Cardiol 2001;37470- 474PubMedGoogle ScholarCrossref
47.
Pepine  CJRouleau  JLAnnis  K  et al.  Effects of angiotensin-converting enzyme inhibition on transient ischemia: the Quinapril Anti-ischemia and Symptoms of Angina Reduction (QUASAR) trial.  J Am Coll Cardiol 2003;422049- 2059PubMedGoogle ScholarCrossref
48.
Morishita  TTsutsui  MShimokawa  H  et al.  Long-term treatment with perindopril ameliorates dobutamine-induced myocardial ischemia in patients with coronary artery disease.  Jpn J Pharmacol 2002;88100- 107PubMedGoogle ScholarCrossref
49.
Dhawan  SSoni  DChandra  NDviwedi  SAgarwal  APuri  VK Use of captopril as an isolated agent for the management of stable angina pectoris--a double blind randomised trial.  Indian Heart J 1992;44(3)151- 154PubMedGoogle Scholar
50.
Thurmann  POdenthal  HJRietbrock  N Converting enzyme inhibition in coronary artery disease: a randomized, placebo-controlled trial with benazepril.  J Cardiovasc Pharmacol 1991;17718- 723PubMedGoogle ScholarCrossref
51.
Bartels  GLvan den Heuvel  FMvan Veldhuisen  DJvan der Ent  MRemme  WJ Acute anti-ischemic effects of perindoprilat in men with coronary artery disease and their relation with left ventricular function.  Am J Cardiol 1999;83332- 336PubMedGoogle ScholarCrossref
52.
Watanabe  HKakihana  MOhtsuka  SSugishita  Y Effects of enalapril during continuous nitrate therapy: analysis of diameter of coronary arteries and platelet cyclic guanosine monophosphate.  Am Heart J 1997;134614- 621PubMedGoogle ScholarCrossref
53.
Metelitsa  VIMartsevich  SYKozyreva  MPSlastnikova  ID Enhancement of the efficacy of isosorbide dinitrate by captopril in stable angina pectoris.  Am J Cardiol 1992;69291- 296PubMedGoogle ScholarCrossref
54.
Klein  WWKhurmi  NSEber  BDusleag  J Effects of benazepril and metoprolol OROS alone and in combination on myocardial ischemia in patients with chronic stable angina.  J Am Coll Cardiol 1990;16948- 956PubMedGoogle ScholarCrossref
55.
Unterberg  CBuchwald  AVogt  AWiegand  V Acute effects of the angiotensin converting enzyme inhibitor ramipril in patients with coronary heart disease [in German].  Med Klin (Munich) 1990;8578- 81PubMedGoogle Scholar
56.
Poole-Wilson  PALubsen  JKirwan  BA  et al.  Effect of long-acting nifedipine on mortality and cardiovascular morbidity in patients with stable angina requiring treatment (ACTION trial): randomised controlled trial.  Lancet 2004;364849- 857PubMedGoogle ScholarCrossref
57.
Raasch  WDendorfer  ABall  BDominiak  P The lipophilic properties of angiotensin-I converting enzyme inhibitors do not influence their diffusion through cultured endothelium.  Jpn J Pharmacol 1999;81346- 352PubMedGoogle ScholarCrossref
58.
Myers  MGPerindopril Multicentre Dose-Response Study Group, A dose-response study of perindopril in hypertension effects on blood pressure 6 and 24 h after dosing.  Can J Cardiol 1996;121191- 1196PubMedGoogle Scholar
59.
Guay  DR Trandolapril: a newer angiotensin-converting enzyme inhibitor.  Clin Ther 2003;25713- 775PubMedGoogle ScholarCrossref
60.
Baudin  BDrouet  L In vitro interactions between ramiprilat and angiotensin I-converting enzyme in endothelial cells.  J Cardiovasc Pharmacol 1989;14 ((suppl 4)) S37- S42PubMedGoogle ScholarCrossref
61.
Sennesael  JAli  ASweny  P  et al.  The pharmacokinetics of perindopril and its effects on serum angiotensin converting enzyme activity in hypertensive patients with chronic renal failure.  Br J Clin Pharmacol 1992;3393- 99PubMedGoogle ScholarCrossref
62.
Chevillard  CJourney  SBree  F  et al.  Compared properties of trandolapril, enalapril, and their diametabolites.  J Cardiovasc Pharmacol 1994;23 ((suppl 4)) S11- S15PubMedGoogle ScholarCrossref
63.
Lonn  EYusuf  SDzavik  V  et al.  Effects of ramipril and vitamin E on therosclerosis: the Study to Evaluate Carotid Ultrasound changes in patients treated with Ramipril and vitamin E (SECURE).  Circulation 2001;103919- 925PubMedGoogle ScholarCrossref
Original Investigation
April 10, 2006

Angiotensin-Converting Enzyme Inhibitors in Patients With Coronary Artery Disease and Absence of Heart Failure or Left Ventricular Systolic Dysfunction: An Overview of Long-term Randomized Controlled Trials

Author Affiliations

Author Affiliations: Department of Cardiology, Hôpital Européen Georges Pompidou (Drs Danchin, Durand, and Kadri) and Hôpital Bichat-Claude Bernard (Dr Steg), Assistance Publique–Hôpitaux de Paris, Paris, Service de Biostatistique, Hôpitaux de Lyon, Lyon (Dr Cucherat), Service de Pharmacologie, Centre Hospitalier Universitaire, Hôpitaux de Rouen, Rouen (Dr Thuillez), France.

Arch Intern Med. 2006;166(7):787-796. doi:10.1001/archinte.166.7.787
Abstract

Background  Results of randomized trials of angiotensin-converting enzyme inhibitors in patients with coronary artery disease (CAD) and preserved left ventricular function are conflicting. We undertook this study to determine whether long-term prescription of angiotensin-converting enzyme inhibitors decreases major cardiovascular events and mortality in patients who have CAD and no evidence of left ventricular systolic dysfunction.

Methods  We searched MEDLINE, EMBASE, and IPA databases, the Cochrane Controlled Trials Register (1990-2004), and reports from scientific meetings (2003-2004), and we reviewed secondary sources. Search terms included angiotensin-converting enzyme inhibitors, coronary artery disease, randomi(s)zed controlled trials, clinical trials, and myocardial infarction. Eligible studies included randomized controlled trials in patients who had CAD and no heart failure or left ventricular dysfunction, with follow-up οf 2 years or longer. Of 1146 publications screened, 7 met our selection criteria and included a total of 33 960 patients followed up for a mean of 4.4 years.

Results  Five trials included only patients with documented CAD. One trial included patients with documented CAD (80%) or patients who had diabetes mellitus and 1 or more additional risk factors, and another trial included patients who had CAD, a history of transient ischemic attack, or intermittent claudication. Treatment with angiotensin-converting enzyme inhibitors decreased overall mortality (odds ratio, 0.86; 95% confidence interval, 0.79-0.93), cardiovascular mortality (odds ratio, 0.81; 95% confidence interval, 0.73-0.90), myocardial infarction (odds ratio, 0.82; 95% confidence interval, 0.75-0.89), and stroke (odds ratio, 0.77; 95% confidence interval, 0.66-0.88). Other end points, including resuscitation after cardiac arrest, myocardial revascularization, and hospitalization because of heart failure, were also reduced.

Conclusion  Angiotensin-converting enzyme inhibitors reduce total mortality and major cardiovascular end points in patients who have CAD and no left ventricular systolic dysfunction or heart failure.

×